ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market... Show more
Oddity Tech is a consumer technology company that builds data-driven, digital-first brands designed to disrupt the offline-dominated beauty and wellness industries. Its portfolio spans IL MAKIAGE (makeup), SpoiledChild (hair and skin care), and METHODIQ (a telehealth dermatology platform). The company's core strategic advantage is a proprietary, artificial intelligence (AI)-enabled platform that serves more than 70 million users, using data science to identify consumer needs and rapidly develop products in response.
That direct-to-consumer (D2C) model — where brands sell straight to shoppers online — has historically supported above-market growth and premium gross margins. However, the 2026 experience exposed a structural vulnerability: the business is highly sensitive to third-party advertising-platform algorithm changes that can suddenly inflate acquisition costs. Management has characterized this as a technical rather than secular issue, and the company retains the option to rebalance toward standard "buy now" offerings instead of its distinctive "try-before-you-buy" approach. Over the medium term, the strategic question is whether Oddity can shift its growth engine from a single scaled brand toward a broader, more resilient multi-brand and multi-category platform.
The most important near-term catalyst is the pace of IL MAKIAGE's CAC normalization. Management has guided for meaningful progress through 2026, with recovery expected as the company's remediation of its advertising-model infrastructure takes hold. Quarterly results will remain a key barometer: the third-quarter 2026 report showed revenue declining only about 2% year over year, a marked improvement from the roughly 25% decline in the second quarter and a sign that the reset may be progressing.
Product and category expansion represents a second catalyst. METHODIQ's early traction, alongside management's plans to broaden its offering into fast-growing areas such as peptides, injectables, and longevity and metabolic health products, could materially expand the addressable market. Capital allocation is also in focus: the company repurchased about 5.6 million shares for roughly $80 million, signaling confidence while preserving a sizable cash cushion.
On the analyst front, the ratings environment has become more cautious. Sell-side consensus has broadly converged on a "Hold" stance, with an average price target in the mid-teens, implying analysts expect the stock to consolidate rather than re-rate higher in the near term. Recent actions include Morgan Stanley raising its target to $18.50 while maintaining an Equal Weight rating, JPMorgan resuming coverage at Neutral, and Jefferies trimming its target to $20, while firms such as Goldman Sachs and Barclays maintain Sell or Underweight views. The direction of future price-target revisions will likely depend on evidence that acquisition costs have structurally normalized.
Oddity operates at the intersection of discretionary consumer spending and digital advertising economics, making it sensitive to several macro forces. Consumer demand for premium beauty and wellness products tends to soften during periods of economic uncertainty, and a slower U.S. consumer backdrop has already prompted some analysts to trim valuation multiples even while leaving underlying growth assumptions largely intact.
Digital advertising cost inflation is perhaps the single most relevant external variable: rising auction prices or platform-algorithm shifts directly affect the company's ability to acquire customers profitably. Interest rates also matter indirectly, shaping both consumer credit conditions and the discount rates applied to high-growth, premium-multiple equities. On the positive side, the secular migration of beauty purchases online, the growth of personalized and efficacy-driven products, and the expansion of telehealth in dermatology all support the company's long-term category tailwinds.
For traders looking to gauge the direction of ODD and similar instruments, Tickeron's Trend Prediction Engine offers an AI-powered forecasting tool designed to help identify whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The platform is built to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments, with searchable categories, historical context, and alert-oriented functionality. Exploring these AI-driven signals can complement fundamental research as you assess the evolving outlook for ODD.
Looking toward 2026 and beyond, the central narrative is whether Oddity can restore durable growth after a transitional year. Management has maintained its medium-term target of roughly 20% revenue growth and a 20% adjusted EBITDA margin — earnings before interest, taxes, depreciation, and amortization — but the timing of that return depends on successful execution of the advertising-model remediation. A recovery to growth for IL MAKIAGE, sustained momentum at SpoiledChild, and continued scaling of METHODIQ would collectively broaden the revenue base and reduce single-brand concentration risk.
Longer-term themes include the expansion of METHODIQ's product range into high-growth wellness categories, the evolution of cost structure and margin sustainability as the company rebalances acquisition strategy, and ongoing competitive threats from both incumbent beauty conglomerates and other digital-native challengers. Regulatory developments in telehealth and advertising data practices could also shape the trajectory. While consensus expectations have reset lower, a credible re-acceleration in the core business could prompt a reassessment of both growth assumptions and the valuation multiple — the key dynamic investors will likely watch through 2026 and into 2027.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ODD has been loosely correlated with ALIT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ODD jumps, then ALIT could also see price increases.
| Ticker / NAME | Correlation To ODD | 1D Price Change % | ||
|---|---|---|---|---|
| ODD | 100% | +5.38% | ||
| ALIT - ODD | 37% Loosely correlated | +5.67% | ||
| RBRK - ODD | 37% Loosely correlated | -0.45% | ||
| CPAY - ODD | 37% Loosely correlated | +1.36% | ||
| ZS - ODD | 37% Loosely correlated | -0.39% | ||
| TOST - ODD | 33% Loosely correlated | +3.46% | ||
More | ||||
| Ticker / NAME | Correlation To ODD | 1D Price Change % |
|---|---|---|
| ODD | 100% | +5.38% |
| Household/Personal Care industry (30 stocks) | 25% Poorly correlated | +2.55% |
| Consumer Non Durables industry (179 stocks) | 11% Poorly correlated | +0.20% |
Industry HouseholdPersonalCare
ODD moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 22 of 24 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The 10-day RSI Indicator for ODD moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ODD as a result. In 51 of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for ODD turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 28 similar instances when the indicator turned negative. In 23 of the 28 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ODD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for ODD moved above the 200-day moving average on October 26, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ODD advanced for three days, in 130 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
ODD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 86 of 111 cases where ODD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating fairly steady price growth. ODD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.826) is normal, around the industry mean (21.731). ODD has a moderately high P/E Ratio (80.720) as compared to the industry average of (16.288). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.518). Dividend Yield (0.000) settles around the average of (0.032) among similar stocks. P/S Ratio (1.521) is also within normal values, averaging (1.902).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.